Abstract:OBJECTIVE:To study the impact of small interference RNA (siRNA) targeting cyclin A2 gene on the growth of MG-63 and HSF cells and to explore whether cyclin A2 siRNAs could become a useful tool in the treatment of osteosarcoma.METHODS:One pair of siRNA targeting the cyclin A2 mRNA and a pair of nonsense siRNA were designed according the current criteria. SiRNA was chemically synthesized and purified. The siRNA was transfected into osteosarcoma cell line MG-63 and normal human skin fibroblast (HSF) cells via oligofectamine. Cells transfected with nonsense siRNA served as the negative control and those only treated with PBS as the blank control group. Quantitative fluorescence RT-PCR, Western-blot, MTT assay, reverse transcriptase (RT)-PCR, flow cytometry and colony-forming test were employed to evaluate the efficacy of RNA interference. At the same time, the mRNA expression of PCNA and cyclin B1 in siRNA treated MG-63 cells were examined.RESULTS:1 nmol/L, 10 nmol/L, 50 nmol/L and 100 nmol/L cyclin A2-siRNA can reduced cyclin A2 mRNA and protein expression respectively by 9.43%, 56.35%, 79.17% and 84.30% as compared with that of the blank control group, whereas the negative and blank control groups had similar expression levels. After 48 h treatment with 10 nmol/L siRNA, MG-63 cells were arrested in G0/G1 phase and the proliferation of this tumor cell was suppressed by 39.06% 48 h after transfection. Furthermore, the treated MG-63 cells showed less colony-forming ability. Increasing the siRNA concentration to 50 nmol/L can further inhibit the proliferation of MG-63 cells by 54.94%. In addition, the cyclin A2-depleted MG-63 cells showed decreased levels of PCNA and cyclin B1. In contrast, although cyclin A2 mRNA and protein expression in HSF reduced 58.13% 48 h after treatment by 50 nmol/L siRNA, these cells exhibited only a slight change in cell cycle, and no clear inhibition of proliferation and impaired plate colony-forming ability was observed.CONCLUSION:Cyclin A2 gene maybe served as a potential target for tumor therapy. RNA interference induces obvious inhibition of cyclin A2 mRNA and protein expression in MG-63 and HSF cells, which consequently downregulate the proliferation of MG-63 cells. There is few inhibitory effect on the proliferation by siRNAs for HSF cells. These results indicate that siRNAs against cyclin A2 could become a potential antiproliferative tool in future antitumor therapy.

Enhanced Chemosensitivity by Simultaneously Inhibiting Cell Cycle Progression and Promoting Apoptosis of Drug-Resistant Osteosarcoma Mg63/Dxr Cells by Targeting Cyclin D1 and Bcl-2

Enhanced Chemosensitivity of Drug-Resistant Osteosarcoma Cells by Lentivirus-Mediated Bcl-2 Silencing

[Knockdown of Cyclin A2 Expression by Small Interfering RNA in MG-63 Cells].

Regulation of Ca2+ Signaling for Drug-Resistant Breast Cancer Therapy with Mesoporous Silica Nanocapsule Encapsulated Doxorubicin/siRNA Cocktail

Enhancing radiosensitivity in osteosarcoma via CDKN2C overexpression: A mechanism involving G1 phase arrest mediated by inhibition of CDK4 expression and Thr172 phosphorylation

Effects of combined c-myc and Bmi-1 siRNAs on the growth and chemosensitivity of MG-63 osteosarcoma cells.

[Growth Inhibition of MG-63 Cells by Cyclin A2 Gene-Specific Small Interfering RNA].

Synergistic treatment of osteosarcoma with biomimetic nanoparticles transporting doxorubicin and siRNA

Sorafenib Inhibits Doxorubicin-Induced PD-L1 Upregulation to Improve Immunosuppressive Microenvironment in Osteosarcoma

The Survivin Suppressant YM155 Reverses Doxorubicin Resistance in Osteosarcoma.

Apoptosis induced by the combination of TRAIL and doxorubicin in osteosarcoma cells

Combination Therapy with Bioengineered Mir-34A Prodrug and Doxorubicin Synergistically Suppresses Osteosarcoma Growth.

Silencing Livin gene expression by RNA interference enhanced the chemotherapeutic sensitivity of drug-resistant MG-63 osteosarcoma cells to doxorubicin

Lentivirus-mediated shRNA targeting insulin-like growth factor-1 receptor (IGF-1R) enhances chemosensitivity of osteosarcoma cells in vitro and in vivo

Co-Delivery of Doxorubicin and Sirna with Reduction and Ph Dually Sensitive Nanocarrier for Synergistic Cancer Therapy

Increase of the Therapeutic Effect on Non-Small-Cell Lung Cancer Cells with Combination Treatment of Shrna Against Cyclin D1 and Bcl-Xl in Vitro

Proliferation Inhibition and Apoptosis Promotion by Dual Silencing of VEGF and Survivin in Human Osteosarcoma.

CXCR4 Blockade Sensitizes Osteosarcoma to Doxorubicin by Inducing Autophagic Cell Death Via PI3K‑Akt‑mTOR Pathway Inhibition.

Blocking CXCR4-CARM1-YAP axis overcomes osteosarcoma doxorubicin resistance by suppressing aerobic glycolysis

Identification Of Gene Expression Profiles Associated With Doxorubicin Resistance In Paired Doxorubicin-Resistant And Doxorubicin-Sensitive Osteosarcoma Cell Lines

Doxorubicin and Sirna Co-Delivery System Based on Carbon Dots Inhibits Chemoresistance of Lung Cancer Through MRP1